Adverse Effects Related to Paediatric Influenza Vaccination and Its Influence on Vaccination Acceptability. The FLUTETRA Study: A Survey Conducted in the Region of Murcia, Spain
Open Access
- 21 June 2024
- journal article
- research article
- Published by Wiley in Influenza and Other Respiratory Viruses
- Vol. 18 (6) , e13331
Abstract
Background: During the 2022–23 season, three autonomous communities recommended influenza vaccination for all children between 6 and 59 months. The objective is to evaluate the adverse effects associated with the administered influenza vaccines in the Region of Murcia, as well as their influence on the recommendation of the same to acquaintances or repetition in future seasons.Material and Methods: Cross‐sectional descriptive study with an online questionnaire sent to the parents of vaccinated minors of 6–23 months of age receiving inactivated intramuscular vaccine (IIV) or 24–59 months of age receiving live‐attenuated intranasal vaccine (LAIV).Results: Among 4971 surveys received, the most common adverse effect for LAIV and IIV was runny nose (40.90%) and local pain (31.94%), respectively. Sixty percent of adverse effects lasted ≤ 1 day, and around 10% lasted ≥ 3 days. The interference of adverse effects with the minor's daily life was very infrequent (3.32%), as was the need for visiting the medical office (2.68%). Overall, 96.44% of parents would recommend influenza vaccination to friends and relatives after the experience. Only 3.56% would not recommend it, while 1.68% would not vaccinate their child against influenza again. The most frequently cited reason being adverse effects.Conclusions: Our study shows the safety of influenza vaccines. Despite the low impact of adverse effects, they influence some parents in their intention to continue vaccinating or recommending it to acquaintances, which remarks the need to reinforce the information given to parents so that this fact does not influence decision‐making.Keywords
Funding Information
- AstraZeneca España
This publication has 11 references indexed in Scilit:
- Adverse Events of Interest Following Influenza Vaccination in the First Season of Adjuvanted Trivalent Immunization: Retrospective Cohort StudyJMIR Public Health and Surveillance, 2022
- Nasal spray live attenuated influenza vaccine: the first experience in Italy in children and adolescents during the 2020–21 seasonItalian Journal of Pediatrics, 2021
- Adverse events of interest vary by influenza vaccine type and brand: Sentinel network study of eight seasons (2010–2018)Vaccine, 2020
- Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in healthy subjects aged 3 to 17 years old: A phase III, open label, single-arm studyVaccine, 2020
- Fever After Influenza, Diphtheria-Tetanus-Acellular Pertussis, and Pneumococcal VaccinationsPediatrics, 2020
- Post licensure surveillance of influenza vaccines in the Vaccine Safety Datalink in the 2013-2014 and 2014-2015 seasonsPharmacoepidemiology and Drug Safety, 2016
- Vaccines against influenza WHO position paper – November 2012.2012
- Live Attenuated Influenza Vaccine (FluMist®; Fluenz™)Drugs, 2011
- Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young childrenVaccine, 2010
- A multinational, randomized, placebo-controlled trial to assess the immunogenicity, safety, and tolerability of live attenuated influenza vaccine coadministered with oral poliovirus vaccine in healthy young childrenVaccine, 2009